Stocks Health care CYCN
NASDAQ · Health careCyclerion Therapeutics, Inc. (CYCN)
It posted a net loss of $6.7M. At June 30, 2026 it held $1.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 4, 2026.
Key facts about Cyclerion Therapeutics, Inc.
- Net worth
- Cyclerion Therapeutics, Inc. has a market value (market cap) of $15.7M at the latest share price, and shareholders' equity of $5.1M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $2.1M (+3.7% year on year), with a net loss of $3.5M.
- Cash flow
- In fiscal 2025 operations used $3.3M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 4, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Cyclerion Therapeutics, Inc.'s next report was expected around November 11, 2026 and is not on file with the SEC yet.
What Cyclerion Therapeutics, Inc. does
Cyclerion Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CYCN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $2.1M | -$3.5M | -$1.11 | n/a |
| 2024 | $2M | -$3.1M | -$1.21 | n/a |
| 2023 | $0 | -$5.3M | -$2.25 | n/a |
| 2022 | $297K | -$44.1M | -$20.28 | -$40.6M |
| 2021 | $3.9M | -$51.6M | -$26.50 | -$36.5M |
| 2020 | $2.3M | -$77.8M | -$51.40 | -$74M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where CYCN ranks in Health care
Latest SEC filings
What Cyclerion Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 5, 2026Preliminary proxy statement PRE 14A
- September 18, 2026Passive stake (5% or more) SCHEDULE 13G
- September 16, 2026Passive stake (5% or more) SCHEDULE 13G
- September 15, 2026Activist stake (5% or more) SCHEDULE 13D
- September 11, 2026Activist stake (5% or more) SCHEDULE 13D
- September 11, 2026
- August 27, 2026
- August 25, 2026Form 425 filing 425
- August 25, 2026Other event 8-K
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
Insider trades
What the people running Cyclerion Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 3 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 14, 2026 | Graul Regina MargaretSee Remarks, Director | Exercised options | 55,849 | $184.3K |
| August 14, 2026 | Graul Regina MargaretSee Remarks, Director | Shares withheld for tax | 48,629 | $184.3K |
| August 14, 2026 | Chicko Rhonda M.Chief Financial Officer | Exercised options | 25,000 | $58.9K |
| July 16, 2026 | Hecht Peter MDirector, 10% owner | Exercised options | 351,037 | - |
Who owns CYCN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Tomas Kiselak13D, may seek influence with 4 related filers | 19.99% | September 11, 2026 |
| Peter M. Hecht13D, may seek influence | 19.4% | July 20, 2026 |
| Fmr LLC13G, passive with 1 related filers | 15% | May 7, 2026 |
| Venrock Healthcare Capital Partners III, L.P.13D, may seek influence with 8 related filers | 9.9% | September 15, 2026 |
| Balyasny Asset Management L.P.13G, passive with 4 related filers | 7.33% | August 14, 2026 |
| ADAR1 Capital Management, LLC13G, passive with 1 related filers | 7% | August 14, 2026 |
| General Atlantic, L.P.13G, passive with 16 related filers | 6.8% | September 18, 2026 |
| Wellington Biomedical Innovation Master Investors (Cayman) II, L.P.13G, passive | 6.1% | September 16, 2026 |
| J. Wood Capital Advisors LLC13G, passive with 1 related filers | 5.4% | October 17, 2025 |
Largest institutional holders
Insiders
3 insiders reported holding 1,042,781 shares in total, about $3.5M at the last price.
| Holder | Shares |
|---|---|
| Hecht Peter MDirector, 10% owner | 910,240 |
| Graul Regina MargaretSee Remarks, Director | 107,523 |
| Chicko Rhonda M.Chief Financial Officer | 25,018 |
Questions about CYCN
What does Cyclerion Therapeutics, Inc. do?
Cyclerion Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as CYCN. Its shares trade on NASDAQ under the ticker CYCN.
What is Cyclerion Therapeutics, Inc.'s net worth?
Cyclerion Therapeutics, Inc. has a market value (market cap) of $15.7M at the latest share price, and shareholders' equity of $5.1M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Cyclerion Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $6.7M.
When did Cyclerion Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 4, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the preliminary proxy statement from October 5, 2026.
When is Cyclerion Therapeutics, Inc.'s next earnings report?
Cyclerion Therapeutics, Inc.'s next report was expected around November 11, 2026 and is not on file with the SEC yet.
Similar companies
Compare CYCN with
Follow CYCN
Get an email when Cyclerion Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Cyclerion Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.